OncoZenge AB (publ) (OM:ONCOZ) Explores Strategic Options for Bupizenge? in China. To Explore Strategic Options for Introduction of Bupizenge in China.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.485 SEK | +0.72% | -0.57% | +12.78% |
May. 21 | OncoZenge AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 08 | Oncozenge AB Appoints Paolo Bossi as Member of the Advisory Board | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+12.78% | 3.85M | |
+40.73% | 739B | |
+31.50% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.53% | 240B | |
+9.53% | 210B | |
-5.36% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- ONCOZ Stock
- News OncoZenge AB
- Oncozenge Explores Strategic Options for Bupizeng in China